Levosimendan Administration and Outcome in Cardiac Surgery

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02275013

Enrollment

159

Registered

2014-10-27

Start date

2006-01-31

Completion date

2013-12-31

Last updated

2014-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Treatment of Left Heart Insufficiency in an Operative Setting of Cardiac Surgery

Brief summary

To assess the effects on outcome of levosimendan with respect to timing of its administration on the postoperative course of high-risk cardiac surgery patients in a retrospective observational study.

Interventions

DRUGLevosimendan

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* patients undergoing cardiac surgery between 2006 and 2013 * levosimendan administration within 24 hours of postoperative ICU admission

Exclusion criteria

* patients younger than 18

Design outcomes

Primary

Measure	Time frame
In-hospital mortality	until discharge, an average of 3 weeks length of stay
1 year follow-up mortality	1 year after surgery

Secondary

Measure	Time frame
Duration of mechanical ventilation	until discharge, an average of 3 weeks length of stay
Incidence of renal dysfunction	until discharge, an average of 3 weeks length of stay
Incidence of renal replacement therapy	until discharge, an average of 3 weeks length of stay

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026